Bristol-Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a strong focus on oncology, immunology, cardiology, and fibrotic diseases, the company utilizes advanced science and research to create life-changing therapies. Bristol-Myers Squibb emphasizes collaboration and partnerships with healthcare professionals, researchers, and patients to enhance treatment outcomes and improve quality of life. The company is committed to addressing unmet medical needs through its comprehensive portfolio of prescription medications and is actively engaged in ongoing research to advance healthcare solutions. Read More
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY)
fell 4.2% in the afternoon session after the company lowered its full-year earnings forecast, overshadowing second-quarter results that beat revenue expectations. The drugmaker trimmed its adjusted earnings per share guidance for 2025, attributing the cut to a $0.57 per share charge from a partnership with BioNTech. This charge also hit second-quarter net income, which fell compared to the prior year. Beyond the one-time charge, the company's results revealed underlying weakness, as sales from its older drugs declined 14% due to generic competition. Specifically, revenue from the cancer drug Revlimid plunged 38% year-over-year. Even though Bristol-Myers raised its annual sales forecast, the reduced profit outlook appeared to sour investor sentiment.
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue guidance of $47 billion at the midpoint came in 1.6% above analysts’ estimates. Its non-GAAP profit of $1.46 per share was 32.6% above analysts’ consensus estimates.
Bristol-Myers Squibb (BMY) offers a high 5.06% dividend yield, strong profitability, and solid financial health, making it a top pick for income investors. Its undervalued stock and consistent payout growth add to its appeal.
U.S. stock futures rose on Thursday after ending on a mixed note on Wednesday. Futures of major benchmark indices were higher, except for the small-cap gauge Russell 2000.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Bristol Myers Squibb (NYSE: BMY, “BMS”) and Bain Capital today announced the creation of a new independent biopharmaceutical company (“NewCo”) focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed company launches with five immunology assets in-licensed from BMS and a $300 million financing commitment that was led by Bain Capital.
Let's delve into the developments on the US markets in the middle of the day on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will oversee the company’s early-stage and late-stage product development across all therapeutic areas.
